For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
The LANCE® Ultra Human E-cadherin Detection Kit is designed for detection and quantitation of human insulin in cell culture media and cell lysates using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.
LANCE and LANCE (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.
Epithelial Cadherin (E-Cadherin), also known as Cadherin-1 or Uvomorulin (in mouse and rat) is a single-pass transmembrane protein that facilitates calcium dependent cell adhesion. A member of the Cadherin family, E-Cadherin utilizes five extracellular EC domains to form cis-clusters between adjacent epithelial cells and trans-clusters within the same cell. Cleavage of the N-terminal domain by a number of proteases is critical for cell motility and EGFR-dependent survival. The intracellular domain of E-cadherin interacts with many proteins including β-catenin, α-catenin, vinculin, and plakoglobin. Lack of binding to any of these proteins has been indicated in cancer metastasis.
|Assay Target Class||Protein|
|Detection Method||Time-Resolved Fluorescence (TRF), TR-FRET|
|Experimental Type||In vitro|
|Product Brand Name||LANCE Ultra|
|Shipping Condition||Blue Ice|
|Unit Size||10,000 Assay Points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater ...